SR 19881

CAS No. 2213490-89-0

SR 19881( —— )

Catalog No. M21956 CAS No. 2213490-89-0

SR 19881 is a full agonist of ERRγ(EC50 value of 0.39 μM in a binding assay and an EC50 value of 4.7 μM in a cell-based assay).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 220 In Stock
2MG 144 In Stock
5MG 202 In Stock
10MG 325 In Stock
25MG 548 In Stock
50MG 769 In Stock
100MG 1051 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    SR 19881
  • Note
    Research use only, not for human use.
  • Brief Description
    SR 19881 is a full agonist of ERRγ(EC50 value of 0.39 μM in a binding assay and an EC50 value of 4.7 μM in a cell-based assay).
  • Description
    SR 19881 is a full agonist of ERRγ(EC50 value of 0.39 μM in a binding assay and an EC50 value of 4.7 μM in a cell-based assay).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Endocrinology/Hormones
  • Target
    Estrogen Receptor/ERR
  • Recptor
    ERRγ
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2213490-89-0
  • Formula Weight
    312.4
  • Molecular Formula
    C19H24N2O2?
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CCN(CC)c1ccc(CCNC(=O)c2ccc(O)cc2)cc1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Lin H , Doebelin C , Patouret, Rémi, et al. Design, synthesis, and evaluation of simple phenol amides as ERRγ agonists[J]. Bioorganic & Medicinal Chemistry Letters, 2018:S0960894X18301987.
molnova catalog
related products
  • WAY-204688

    WAY-204688 is a selective and orally active estrogen receptor inhibitor of NF-κB transcriptional activity (IC50 = 122 nM in HAECT-1 cells).

  • Aquacrine

    Estrone is an estrogenic hormone.

  • Medicarpin (b)

    (+)-Medicarpin potently inhibits osteoclastogenesis and promotes bone healing and increases bone mass by osteoblast differentiation with estrogen receptor (ER) β-mediated osteogenic action.